Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allergic Reactions

Allergic Reactions

Allergic Reactions: Anaphylaxis

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Cross-reactivity

Cross-reactivity

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Hymenoptera venom allergy].

Ugeskrift for laeger·2025

Same author

ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

Clinical and translational allergy·2021

Same author

[Anaphylaxis in children and adults].

Ugeskrift for laeger·2020

Same author

2019 ARIA Care pathways for allergen immunotherapy.

Allergy·2019

Same author

Test methods for estimating the efficacy of the fast-acting disinfectant peracetic acid on surfaces of personal protective equipment.

Journal of applied microbiology·2017

Same author

Proficiency testing of skin prick testers as part of a quality assurance system.

Clinical and translational allergy·2016

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Allergen-specific immunotherapy with recombinant allergens.

G Pauli¹, Hans-Jørgen Malling

¹Université de Strasbourg, Strasbourg, France.

Current Topics in Microbiology and Immunology

|March 16, 2011

Summary

This summary is machine-generated.

Recombinant allergens show promise for treating allergic rhinitis and asthma, offering improved efficacy and defined quality compared to traditional extracts. However, further large-scale studies are needed to confirm their safety and overall value.

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Area of Science:

Allergy and Immunology
Biotechnology
Clinical Medicine

Background:

Subcutaneous immunotherapy (SCIT) is established for allergic rhinitis and asthma.
Current SCIT uses crude extracts with variable allergen content and potential for off-target sensitization.
Anaphylactic side effects are a significant limitation of traditional SCIT.

Purpose of the Study:

To evaluate the clinical efficacy and safety of recombinant allergens in immunotherapy.
To compare recombinant allergens with conventional allergenic extracts.
To explore the potential of defined molecules for improved immunotherapy.

Main Methods:

Proof-of-concept studies utilizing recombinant allergens.
Clinical trials involving Phleum pratense (grass) and Betula (birch) allergens.
Dosage comparisons using defined protein mass units and allergen dosages.

Main Results:

A mixture of five Phleum pratense allergens demonstrated ~40% reduction in disease severity.
Recombinant and purified Bet v 1 showed ~60% additional efficacy compared to birch extract.
Higher frequency of systemic side effects noted with grass allergens; no efficacy with Bet v 1 fragments/trimer.

Conclusions:

Recombinant allergens offer a well-defined, consistent alternative to crude extracts for immunotherapy.
Clinical efficacy has been demonstrated in proof-of-concept studies.
Further large-scale clinical trials are essential to determine the definitive efficacy and safety profile of recombinant allergen immunotherapy.